Navigation Links
Novalar Receives FDA Approval for OraVerse(TM)
Date:5/12/2008

s transient injection site pain. Although tachycardia and cardiac arrhythmia may occur with the parenteral use of alpha-adrenergic blocking agents, such events are uncommon after submucosal administration of OraVerse.

"The Novalar team is extremely excited to bring to market a first-in-class product with such strong interest from both patients and dentists," added Ms. Janson. "It is seldom that a company is able to conceive, develop and market such an innovative product that has the ability to change the standard of care in dentistry. Novalar is committed to making OraVerse a commercial success and believes we are well positioned to bring additional dental pharmaceuticals to market through our unique development capabilities."

About OraVerse

OraVerse (phentolamine mesylate) Injection is the only local anesthetic reversal agent that accelerates the return to normal sensation and function following restorative and periodontal maintenance procedures. OraVerse is indicated for the reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than six years of age or weighing less than 15 kg (33 lbs).

About Novalar

Novalar is a specialty pharmaceutical company that partners directly with dental professionals to enrich the patient experience. The company is uniquely positioned to develop targeted oral pharmaceutical products and translate the full value of these novel solutions to clinical practice. For more information, please visit http://www.novalarpharm.com.


'/>"/>
SOURCE Novalar Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
2. U.S. Navy Receives Funding for Further Development of Hemopure(R)
3. UCSF receives funding for building from California stem cell agency
4. USC receives nearly $27 million in funding for new stem cell research facility
5. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
6. Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence
7. Boston Medical Center/Boston University School of Medicine researcher receives award
8. Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug
9. Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification
10. Vascular Insights Receives FDA Clearance for Infusion Catheter
11. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...e Royal Women's Hospital has found that the most c...nduced labor.// Nearly one-third of the women with... caesarians. The factors enhancing the risk of a C...st-time mothers. "The message we are taking is t...
... the University at Buffalo probing into the effect...fish as a model, have zeroed in on many proteins i...negatively with severe alcohol exposure. The scien... out after prolonged alcohol exposure, after they ...
...inister Anbumani Ramadoss has added a new twist to...angerous even without the added pesticides.// "Al...high-risk factors as much as tobacco and a compreh...ed," he said at the golden jubilee year celebratio...
...e University of South Florida College of Medicine ...in Florida is discouraging medical students// from...cialization. The situation means that many people ...n Deutsch, MD, lead author of the study and chief ...
Other Medicine News:Health News:Brain protein expression can be damaged with prolonged alcohol exposure 2Health News:Malpractice Worry Discouraging Medical Students From Taking Up Obstetrics And Gynecology 2
(Date:7/23/2008)... WASHINGTON, July 23 /PRNewswire-USNewswire/ --... of Justice:, Chairman Conyers, Ranking Member Sm...he opportunity to testify today., Since I appeare...ave,become even better acquainted with the talente...tment and with the work they do, and I have come t...
(Date:7/23/2008)... ASPS Study Finds Some Areas of the Body Have G...IGHTS, Ill., July 23 /PRNewswire-USNewswire/ -- Fa...hrough liposuction was found to be,an excellent so...ations,than other areas of the body, reports a Bra...ructive Surgery(R), the official medical journal o...
(Date:7/23/2008)... SEATTLE, July 23 /- Den... that it expects the Independent Data,Monitoring C...rim analysis,of overall survival relating to the C...e AdenoCarcinoma Treatment, also known as D9902B) ...ENGE is the Company,s investigational,active cellu...
(Date:7/22/2008)... BRISBANE, Australia, July 22 /PRNewswire-First...d late yesterday, the Board of Progen,Pharmaceutic...ed that it,had discontinued the PI-88 phase 3 stud...direction to develop its existing portfolio of com...re additional compounds and,opportunities through ...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Looking at neurons from all sides 3069 1Looking at neurons from all sides 3069 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 1deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 5Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 1Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 1Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 9
...DNEY, Australia, March 14, 2007 /Xinhua-PRNewswire...day announced the results,from its Phase II trial ...lmonary Disease (COPD), a respiratory disease,affe...l was conducted in 79 diagnosed COPD patients at 1...he trial was to,determine if subjects that were po...
...pany anticipates second quarter BLA filing for C1-... 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceutical...m,its pivotal U.S. Phase III trial of C1-esterase ...ditary angioedema (HAE). In the,acute study, which...tor in Hereditary Angioedema Nanofiltration Genera...
Other Medicine Technology:Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: